BVS Bioventus Inc

Price (delayed)

$7.55

Market cap

$601.09M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.34

Enterprise value

$967.16M

Bioventus delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The Innovations ...

Highlights
Bioventus's EPS has soared by 93% YoY and by 86% from the previous quarter
The company's net income has surged by 92% YoY and by 86% QoQ
The quick ratio has declined by 4.4% since the previous quarter but it rose by 3.6% year-on-year
Bioventus's equity has decreased by 9% YoY

Key stats

What are the main financial stats of BVS
Market
Shares outstanding
79.61M
Market cap
$601.09M
Enterprise value
$967.16M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.49
Price to sales (P/S)
0.92
EV/EBIT
46.48
EV/EBITDA
13.16
EV/Sales
1.85
Earnings
Revenue
$522.74M
EBIT
$20.81M
EBITDA
$73.49M
Free cash flow
$2.76M
Per share
EPS
-$0.34
Free cash flow per share
$0.04
Book value per share
$2.16
Revenue per share
$8.25
TBVPS
$4.99
Balance sheet
Total assets
$794.24M
Total liabilities
$576.81M
Debt
$391.24M
Equity
$171.28M
Working capital
$92.58M
Liquidity
Debt to equity
2.28
Current ratio
1.53
Quick ratio
0.87
Net debt/EBITDA
4.98
Margins
EBITDA margin
14.1%
Gross margin
65.5%
Net margin
-4.1%
Operating margin
-4.8%
Efficiency
Return on assets
-2.7%
Return on equity
-12.3%
Return on invested capital
4.1%
Return on capital employed
3.4%
Return on sales
4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BVS stock price

How has the Bioventus stock price performed over time
Intraday
2.58%
1 week
4.86%
1 month
33.16%
1 year
115.71%
YTD
43.26%
QTD
31.3%

Financial performance

How have Bioventus's revenue and profit performed over time
Revenue
$522.74M
Gross profit
$342.65M
Operating income
-$25.3M
Net income
-$21.65M
Gross margin
65.5%
Net margin
-4.1%
BVS's net margin has soared by 93% YoY and by 87% QoQ
The company's net income has surged by 92% YoY and by 86% QoQ
The operating income has soared by 91% YoY and by 79% from the previous quarter
Bioventus's operating margin has surged by 91% YoY and by 80% QoQ

Growth

What is Bioventus's growth rate over time

Valuation

What is Bioventus stock price valuation
P/E
N/A
P/B
3.49
P/S
0.92
EV/EBIT
46.48
EV/EBITDA
13.16
EV/Sales
1.85
Bioventus's EPS has soared by 93% YoY and by 86% from the previous quarter
BVS's price to book (P/B) is 79% more than its last 4 quarters average of 1.9
Bioventus's equity has decreased by 9% YoY
BVS's P/S is 78% above its last 4 quarters average of 0.5
The revenue is up by 2% since the previous quarter

Efficiency

How efficient is Bioventus business performance
The return on invested capital has surged by 119% since the previous quarter and by 108% year-on-year
Bioventus's ROS has soared by 118% from the previous quarter and by 107% YoY
The return on assets has surged by 89% year-on-year and by 86% since the previous quarter
The ROE has soared by 86% year-on-year and by 86% since the previous quarter

Dividends

What is BVS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BVS.

Financial health

How did Bioventus financials performed over time
Bioventus's total assets is 38% more than its total liabilities
Bioventus's total liabilities has decreased by 11% YoY and by 2.2% QoQ
Bioventus's total assets has decreased by 10% YoY and by 2.1% from the previous quarter
BVS's debt is 128% higher than its equity
BVS's debt is down by 12% YoY
Bioventus's equity has decreased by 9% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.